PT  - JOURNAL ARTICLE
AU  - KÖSTLER, WOLFGANG J.
AU  - STEGER, GÜNTHER G.
AU  - OLEIMAN, AFSCHIN
AU  - SCHWAB, BARBARA
AU  - SINGER, CHRISTIAN F.
AU  - TOMEK, SANDRA
AU  - BRODOWICZ, THOMAS
AU  - KRAINER, MICHAEL
AU  - WILTSCHKE, CHRISTOPH
AU  - HORVAT, REINHARD
AU  - JAKESZ, RAIMUND
AU  - ZIELINSKI, CHRISTOPH C.
TI  - Monitoring of Serum Her-2/<em>neu</em> Predicts Histopathological Response to Neoadjuvant Trastuzumab-based Therapy for Breast Cancer
DP  - 2004 Mar 01
TA  - Anticancer Research
PG  - 1127--1130
VI  - 24
IP  - 2C
4099  - http://ar.iiarjournals.org/content/24/2C/1127.short
4100  - http://ar.iiarjournals.org/content/24/2C/1127.full
SO  - Anticancer Res2004 Mar 01; 24
AB  - Background: This prospective pilot study was performed to elucidate whether early changes in serum levels of the Her-2/neu extracellular domain (ECD) reflect histopathological response to trastuzumab-based neoadjuvant therapy in patients with Her-2/neu-overexpressing breast cancer. Patients and Methods: ECD levels were measured throughout neoadjuvant trastuzumab-based treatment in 16 patients using a Her-2/neu Microtiter ELISA. Results: In 9 (56%) patients with Her-2/neu shedding tumors (ECD >15ng/ml), ECD values (in % of baseline) of non-responders vs. responders were 117% vs. 55% on day 8 (p=0.014), 157% vs. 58% on day 22 (p=0.061) and 114% vs. 46% at restaging (p=0.049). Conclusion: Serial monitoring of serum Her-2/neu ECD levels may represent a valuable tool to predict pathological response to trastuzumab-based neoadjuvant therapy in patients with Her-2/neu-overexpressing tumors. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved